Studies

1 April, 2022

BEYOND

2024-02-07T15:52:23+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: |

Completed study Official Study Title Bezlotoxumab Υielded Οutcomes by addressing personalized Needs in Clostridioides Difficile infection: the BEYOND double-blind randomized clinical trial Brief Description Previous data from our group have shown that integrated information from SNPs of the host DNA, IL-8 and the enrichment of the stool microbiome can indicate the patients with infection

1 July, 2021

ImmunoSep

2024-12-10T23:02:24+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

ImmunoSep: The Hellenic Institute for the Study of Sepsis Announces the Successful Evaluation of the ImmunoSep Project by the European Commission Ongoing study Official Study Title Personalized Immunotherapy in Sepsis: a multicentre and multinational, double-blind, double-dummy randomized clinical trial Brief Description Previous findings coming from the randomized clinical trial PROVIDE have showed

23 April, 2021

FERMIN

2023-01-15T21:59:11+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: |

Completed study Official Study Title FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial) Brief Description FERMIN is a randomized clinical trial aiming to assess the clinical impact of fenofibrate to improve clinical outcomes in patients with COVID-19. Details Status: Completed Study Type: Interventional (Clinical Trial)

1 January, 2021

ACCESS

2024-02-07T15:52:51+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia to attenuatE inflammatory responseS and improve outcomeS Brief Description Based on evidence coming from observational studies that addition of macrolides in the treatment regimen of community-acquired pneumonia (CAP) exhibits some anti-inflammatory mode of action, this RCT is aiming to

1 December, 2020

SAVE-MORE

2024-03-14T14:28:56+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early Management Of seveRE respiratory failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial Brief Description SAVE-MORE is a double-blind randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by

1 June, 2020

ACTIVATE-II

2023-01-09T12:12:57+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title A randomized clinical trial for enhanced trained immune responses through Bacillus Calmette-Guérin vaccination to prevent infections by COVID-19 Brief Description ACTIVATE-II is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination exists in

1 May, 2020

ACHIEVE

2023-01-09T12:17:31+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory

1 April, 2020

SAVE

2024-10-18T12:29:07+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker

1 April, 2020

ESCAPE

2023-01-09T12:13:22+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: , |

Completed study Official Study Title Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach Brief Description ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous

1 November, 2019

INCREDIBLE-ME

2023-01-09T12:12:10+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Gut-derived INCREtin hormones in the pathophysiology of Type 1 DiaBetes MeLlitus; Effect of Metformin treatment (the INCREDIBLE-ME trial) Brief Description INCREDIBLE-ME is a randomized clinical trial aiming to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion.

Go to Top